Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11299461 | 0.82 | ALDH1A1 (0.48) | NPSR1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL15052306 | 0.82 | NPSR1 (0.40) | NPSR1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL8489891 | 0.78 | THRB (0.50) | NPSR1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL15071778 | 0.77 | NPSR1 (0.48) | NPSR1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL18031825 | 0.77 | CYP17A1 (0.38) | NPSR1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL1960823 | 0.76 | THRB (0.48) | ALDH1A1 | |
| SCHEMBL16807402 | 0.76 | NPSR1 (0.47) | NPSR1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL7131314 | 0.75 | ALDH1A1 (0.42) | NPSR1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL7120797 | 0.75 | ALDH1A1 (0.42) | NPSR1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL134550 | 0.75 | CYP17A1 (0.51) | NPSR1ALDH1A1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130164674-A1 | NOVEL ACRYL MONOMER, POLYMER AND RESIST COMPOSITION COMPRISING SAME | KOREA KUMHO PETROCHEMICAL CO., LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
| US-20130164674-A1 | NOVEL ACRYL MONOMER, POLYMER AND RESIST COMPOSITION COMPRISING SAME | KOREA KUMHO PETROCHEMICAL CO., LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
| US-20130164674-A1 | NOVEL ACRYL MONOMER, POLYMER AND RESIST COMPOSITION COMPRISING SAME | KOREA KUMHO PETROCHEMICAL CO., LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
| US-7977442-B2 | Radiation-sensitive composition, polymer and monomer | JSR CORPORATION (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977442-B2 | Radiation-sensitive composition, polymer and monomer | JSR CORPORATION (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20100331440-A1 | RADIATION-SENSITIVE COMPOSITION, POLYMER AND MONOMER | JSR CORPORATION (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100331440-A1 | RADIATION-SENSITIVE COMPOSITION, POLYMER AND MONOMER | JSR CORPORATION (JP) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130164674-A1 | NOVEL ACRYL MONOMER, POLYMER AND RESIST COMPOSITION COMPRISING SAME | SMC1A, SMCHD1, SMC2 | NPSR1 3301/4885ALDH1A1 652/4885MEN1 1959/4885 |
| US-20100331440-A1 | RADIATION-SENSITIVE COMPOSITION, POLYMER AND MONOMER | ALG1, MRE11, PCNA | NPSR1 3881/4885ALDH1A1 2187/4885MEN1 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.